¼¼°èÀÇ ÀǾàǰ ¾à¹°Àü´Þ ½ÃÀå
Pharmaceutical Drug Delivery
»óǰÄÚµå : 1777425
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 301 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀǾàǰ ¾à¹°Àü´Þ ½ÃÀåÀº 2030³â±îÁö 2Á¶ 4,000¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 1Á¶ 9,000¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀǾàǰ ¾à¹°Àü´Þ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 4.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2Á¶ 4,000¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °æ±¸ Åõ¿©´Â CAGR 5.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6,280¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÁÖ»çÁ¦ Åõ¿© ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5,106¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀǾàǰ ¾à¹°Àü´Þ ½ÃÀåÀº 2024³â¿¡ 5,106¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 4,961¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.9%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.7%¿Í 3.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÀǾàǰ ¾à¹°Àü´Þ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±â¼úÀÇ ¹ßÀüÀº ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

¾à¹°Àü´Þ ½ÃÀåÀº À¯È¿¼º, ¾ÈÀü¼º, ȯÀÚ ¼øÀÀµµ Çâ»óÀ» À§ÇÑ ²÷ÀÓ¾ø´Â ±â¼ú ¹ßÀüÀ¸·Î ÃÖ±Ù ÆÐ·¯´ÙÀÓÀÇ ÀüȯÀÌ ÀϾ°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ °æ±¸Á¦³ª ÁÖ»çÁ¦¸¦ ÅëÇÑ ¾à¹°Àü´Þ ¹æ½ÄÀº ³ª³ë±â¼ú ±â¹ÝÀÇ Ä³¸®¾î, ½º¸¶Æ® ¾à¹°Àü´Þ ½Ã½ºÅÛ, À̽ÄÇü ÀåÄ¡¿Í °°Àº ÃÖ÷´Ü ±â¼ú Çõ½Å¿¡ ÀÇÇØ º¸¿ÏµÇ°í ÀÖÀ¸¸ç, °æ¿ì¿¡ µû¶ó¼­´Â ´ëüµÇ°í ÀÖ½À´Ï´Ù. ¸®Æ÷Á», µ§µå¸®¸Ó, °íºÐÀÚ ³ª³ëÀÔÀÚ µîÀÇ ³ª³ë ij¸®¾î´Â Á¤È®ÇÑ Å¸°ÙÆÃ ±â´ÉÀ» Á¦°øÇÏ¿© »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃŰ¸é¼­ Àü½Å ºÎÀÛ¿ëÀ» °¨¼Ò½Ãŵ´Ï´Ù. ¸¶ÀÌÅ©·ÎĨ, ¹ÙÀÌ¿À¼¾¼­ µîÀÇ ½º¸¶Æ® ¾à¹°Àü´Þ ½Ã½ºÅÛÀº Á¦¾îµÈ ¼­¹æÇü ¹æÃâÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ȯÀÚÀÇ ºÎ´ãÀ» ÃÖ¼ÒÈ­Çϸ鼭 ÃÖÀûÀÇ Ä¡·á È¿°ú¸¦ º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, ¾à¹°Àü´Þ¿¡ ÀΰøÁö´É(AI)À» ÅëÇÕÇÏ¿© °³ÀÎÈ­µÈ Ä¡·á ¿ä¹ýÀ» À§ÇÑ ¿¹Ãø ºÐ¼®À» ¿ëÀÌÇÏ°Ô Çϰí, ¾à¹° Åõ¿© Àü·«À» ´õ¿í ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ °íºÐÀÚ ¾à¹°¿¡ ¸Â´Â »õ·Î¿î Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ °³¹ßÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¿þ¾î·¯ºí ÁÖ»ç±â ¹× ÀÚµ¿ ÁÖ»ç±â¸¦ Æ÷ÇÔÇÑ ÀÚ°¡ Åõ¾à ÀåÄ¡´Â ȯÀÚ Áß½ÉÀÇ ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÈíÀÔ ¹× °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛµµ ÁøÈ­Çϰí ÀÖÀ¸¸ç, ¹Ì¸³ÀÚ ±â¼ú°ú À̿ Æ÷·¹½Ã½º¸¦ Ȱ¿ëÇÏ¿© º¸´Ù È¿À²ÀûÀÎ Èí¼ö¸¦ ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÀüüÀûÀ¸·Î º¸´Ù È¿À²ÀûÀ̰í Á¤È®Çϸç ÃÖ¼Ò Ä§½ÀÀûÀÎ ¾à¹°Àü´ÞÀ» ½ÇÇöÇÏ´Â µ¥ ±â¿©Çϰí ÀÖÀ¸¸ç, Á¦¾à¾÷°èÀÇ Ä¡·á ¹æ¹ý¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

¾à¹°Àü´Þ ±â¼úÀÇ ÁøÈ­¸¦ ÃËÁøÇÏ´Â ½ÃÀå µ¿ÇâÀº?

¼¼°è ¾à¹°Àü´Þ ½ÃÀåÀº ÀÌ ºÐ¾ßÀÇ ¹Ì·¡¸¦ ÀçÁ¤ÀÇÇÏ´Â »õ·Î¿î Æ®·»µå¿¡ ÈûÀÔ¾î Àü·Ê ¾ø´Â Çõ½ÅÀÇ ¹°°á¿¡ È۽ο© ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Æ®·»µå Áß Çϳª´Â »ý¹°ÇÐÀû Á¦Á¦¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ±ÞÁõÀ¸·Î, Áö¼ÓÇü ÁÖ»çÁ¦, Ç¥Àû ³ª³ëÁ¦Á¦Á¦ µî »õ·Î¿î Àü´Þ ¸ÞÄ¿´ÏÁòÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ½ÉÇ÷°üÁúȯ, ¾Ï µî ¸¸¼ºÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¹¾à ¼øÀÀµµ¸¦ ³ôÀ̰í, ³»¿ø Ƚ¼ö¸¦ ÁÙÀ̸ç, ȯÀÚ Ä£È­ÀûÀÎ ¾à¹° Åõ¿© ¹æ¹ý¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀÌ¼Ç ¹× µðÁöÅÐ Çコ Ç÷§Æû°ú ÅëÇÕÇÏ¿© ȯÀÚÀÇ ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ½Ç½Ã°£ µ¥ÀÌÅÍ ÃßÀûÀ» °¡´ÉÇÏ°Ô ÇÏ´Â Ä¿³ØÆ¼µå ¾à¹°Àü´Þ ±â±âÀÇ º¸±ÞÀÌ È®»êµÇ°í ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ µÎµå·¯Áø Ãß¼¼´Â ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ¾à¹°Àü´Þ ±â¼ú·ÎÀÇ ÀüȯÀÔ´Ï´Ù. Á¦Æ® ÀÎÁ§ÅÍ, ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡, ºñ°­ ½ºÇÁ·¹ÀÌ¿Í °°Àº Çõ½ÅÀº ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀ̸鼭 ¼øÀÀµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 3D ÇÁ¸°ÆÃ ±â¼úÀº ¹æÃâ ÇÁ·ÎÆÄÀÏÀ» Á¦¾îÇϴ ȯÀÚº° ¾à¹° Á¦Á¦¸¦ Á¦Á¶ÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Áö¼Ó °¡´ÉÇÏ°í »ýºÐÇØ °¡´ÉÇÑ ¾à¹°Àü´Þ ¹°Áú¿¡ ´ëÇÑ ¼ö¿äµµ ȯ°æ ¹®Á¦¿Í ±ÔÁ¦ ¾Ð·Â¿¡ ÈûÀÔ¾î Áõ°¡¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ģȯ°æ Á¦Á¦¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ¾à¹°Àü´Þ ¹æ½ÄÀÌ ¼¼°è Áö¼Ó°¡´É¼º ÀÌ´Ï¼ÅÆ¼ºê¿¡ ºÎÇÕÇϵµ·Ï ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼ÀÇ À¶ÇÕÀº Ä¡·á È¿°ú¸¦ ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó ¾÷°è ÀÌÇØ°ü°èÀڵ鿡°Ô »õ·Î¿î ½ÃÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

ÃÖÁ¾ ¿ëµµ´Â ¾à¹°Àü´ÞÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇÒ °ÍÀΰ¡?

¾à¹°Àü´Þ ±â¼úÀÇ ¹ßÀüÀº ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß·ÎÀÇ Àû¿ë°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖÀ¸¸ç, ´Ù¾çÇÑ ÃÖÁ¾ »ç¿ë ºÐ¾ß°¡ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á´Â º¹ÀâÇϰí Ç¥ÀûÈ­µÈ Ä¡·á°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Çõ½ÅÀÌ °¡Àå Áß¿äÇÑ ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. Ç×ü ¾à¹° º¹ÇÕü(ADC), ³ª³ë ij¸®¾î, °íºÐÀÚ ¾à¹° º¹ÇÕü µî ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ¾à¹°ÀÇ ¼±ÅüºÀ» Çâ»ó½Ã۰í Àü½Å µ¶¼ºÀ» °¨¼Ò½ÃÅ´À¸·Î½á ¾Ï Ä¡·á¿¡ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ÁßÃ߽Űæ°è(CNS) ÁúȯÀÇ Ä¡·á´Â Ç÷¾×³úÀ庮(BBB) Åõ°ú ±â¼úÀÇ ºñ¾àÀûÀÎ ¹ßÀüÀ¸·Î ½Å°æ Ä¡·áÁ¦¸¦ º¸´Ù È¿°úÀûÀ¸·Î Àü´ÞÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

°¨¿°º´°ú ¹é½Å °³¹ßµµ ƯÈ÷ Äڷγª19 »çŸ¦ °è±â·Î ¸Å¿ì Áß¿äÇÑ ºÐ¾ß°¡ µÇ¾ú½À´Ï´Ù. ÁöÁú ³ª³ëÀÔÀÚ(LNP)´Â ȹ±âÀûÀÎ ±â¼ú·Î µîÀåÇÏ¿© mRNA ¹é½Å Àü´Þ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °æÇÇ-°æÆó ¾à¹°Àü´Þ ½Ã½ºÅÛµµ ù ¹øÂ° Åë°ú ´ë»ç¸¦ ¿ìȸÇÏ´Â ´É·ÂÀ¸·Î Ä¡·áÁ¦ÀÇ ³ôÀº »ýü ÀÌ¿ë·üÀ» È®º¸ÇÒ ¼ö ÀÖ¾î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀçÅÃÄ¡·á ¹× ÀÚ°¡ Åõ¾à¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÚµ¿ ÁÖ»ç±â, ÀåÂøÇü ÁÖÀÔ ÆßÇÁ, ÇÁ¸®Çʵå½Ã¸°Áö¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÏ¿© °í·ÉÈ­ ¹× ¸¸¼º ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ ¿ä±¸¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ°¡ °è¼Ó ´Ù¾çÈ­µÇ´Â °¡¿îµ¥, Á¦¾à»çµéÀº ¾à¹°Àü´Þ ¸ÞÄ¿´ÏÁòÀ» ƯÁ¤ Ä¡·á ¿µ¿ª¿¡ ÀûÇÕÇϵµ·Ï ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ Áúȯ ¿µ¿ª¿¡¼­ ÃÖÀûÀÇ Ä¡·á È¿°ú¸¦ º¸ÀåÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¾à¹°Àü´Þ ½ÃÀå È®´ë ¿äÀÎÀº?

¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ±â¼ú Çõ½Å, ¸¸¼º Áúȯ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ±ÞÁõÀº ÁÖ¿ä ÃËÁø¿äÀÎÀ̸ç, °íºÐÀÚ Ä¡·áÁ¦ÀÇ ¾ÈÁ¤¼º°ú È¿´ÉÀ» º¸ÀåÇϴ ÷´Ü ¾à¹°Àü´Þ ¼Ö·ç¼ÇÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Ä¿³ØÆ¼µå ÈíÀÔ±â, ¿þ¾î·¯ºí ÁÖ»ç±â µî ½º¸¶Æ® ¾à¹°Àü´Þ ÀåÄ¡ÀÇ º¸±ÞÀº Ä¡·á ¼øÀÀµµ¸¦ ³ôÀÌ°í ½Ç½Ã°£ °Ç°­ ¸ð´ÏÅ͸µ ±â´ÉÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾à¹° Á¦Á¦¿¡¼­ ³ª³ë±â¼úÀÇ ºÎ»óÀº Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí, Ç¥Àû ¾à¹°Àü´Þ°ú Àü½Å ³ëÃâÀ» ÁÙÀÏ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

ȯÀÚ Áß½ÉÀÇ ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øµµ ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÚµ¿ ÁÖ»ç±â, ÇÁ¸®Çʵå½Ã¸°Áö µî ÀÚ°¡Åõ¿© ÀåÄ¡·ÎÀÇ ÀüȯÀº ¸¸¼ºÁúȯ ȯÀÚÀÇ º´¿ø ÀÇÁ¸µµ¸¦ ÁÙÀ̰í Ä¡·á ¿ä¹ýÀ» °£¼ÒÈ­ÇÒ Çʿ伺¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡¼­ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº ¿¹Ãø ºÐ¼®À» °­È­Çϰí, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ Åõ¾à ÀÏÁ¤À» ÃÖÀûÈ­ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, 3D ÇÁ¸°ÆÃ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¸ÂÃãÇü ¾à¹° Á¦Á¦ °³¹ßÀÌ ¿ëÀÌÇØÁ® ´Ù¾çÇÑ È¯ÀÚ Áý´ÜÀÇ Ä¡·á °á°ú°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀÌ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ Áö¼ÓÇÏ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÌ °áÇյǸ鼭 ¾à¹°Àü´Þ ½ÃÀåÀº Çõ½Å°ú Á¢±Ù¼ºÀÇ »õ·Î¿î ½Ã´ë¸¦ ¸ÂÀÌÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Åõ¿© °æ·Î(°æ±¸ Åõ¿©, ÁÖ»ç Åõ¿©, ±¹¼Ò Åõ¿©, ¾È±¸ Åõ¿©, Æó Åõ¿©, ±âŸ Åõ¿© °æ·Î), ¿ëµµ(¾Ï¿ëµµ, CVD ¿ëµµ, ´ç´¢º´ ¿ëµµ, È£Èí±âÁúȯ ¿ëµµ, ÁßÃ߽ŰæÁúȯ ¿ëµµ, ÀÚ°¡¸é¿ªÁúȯ ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pharmaceutical Drug Delivery Market to Reach US$2.4 Trillion by 2030

The global market for Pharmaceutical Drug Delivery estimated at US$1.9 Trillion in the year 2024, is expected to reach US$2.4 Trillion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$628.0 Billion by the end of the analysis period. Growth in the Injectable Administration segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$510.6 Billion While China is Forecast to Grow at 7.9% CAGR

The Pharmaceutical Drug Delivery market in the U.S. is estimated at US$510.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$496.1 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Pharmaceutical Drug Delivery Market - Key Trends & Drivers Summarized

How Is Technological Advancement Reshaping Drug Delivery Systems?

The pharmaceutical drug delivery market has witnessed a paradigm shift in recent years, driven by relentless technological advancements aimed at enhancing efficacy, safety, and patient compliance. Traditional oral and injectable drug delivery methods are now being complemented and, in some cases, replaced by cutting-edge innovations such as nanotechnology-based carriers, smart drug delivery systems, and implantable devices. Nanocarriers, including liposomes, dendrimers, and polymeric nanoparticles, offer precise targeting capabilities, reducing systemic side effects while improving bioavailability. Smart drug delivery systems, such as microchips and biosensors, enable controlled and sustained release, ensuring optimal therapeutic effects while minimizing patient burden. Additionally, the integration of artificial intelligence (AI) in drug delivery is facilitating predictive analytics for personalized treatment regimens, further optimizing drug administration strategies.

Moreover, advancements in biologics have necessitated the development of novel delivery mechanisms tailored to large-molecule drugs. Self-administrative devices, including wearable injectors and autoinjectors, have gained traction, addressing the growing demand for patient-centric healthcare solutions. Inhalation and transdermal drug delivery systems are also evolving, leveraging microparticle technology and iontophoresis for more efficient absorption. These advancements collectively contribute to a more efficient, precise, and minimally invasive drug delivery landscape, reshaping the pharmaceutical industry’s approach to treatment modalities.

What Market Trends Are Driving the Evolution of Drug Delivery Technologies?

The global pharmaceutical drug delivery market is experiencing an unprecedented wave of innovation, underpinned by emerging trends that are redefining the sector’s future. One of the most significant trends is the surge in biologics and biosimilars, necessitating novel delivery mechanisms such as long-acting injectables and targeted nanoformulations. With the increasing prevalence of chronic diseases like diabetes, cardiovascular disorders, and cancer, there is a rising demand for patient-friendly drug administration methods that enhance adherence and reduce hospital visits. This has led to a proliferation of connected drug delivery devices that integrate with mobile applications and digital health platforms, enabling remote patient monitoring and real-time data tracking.

Another prominent trend is the shift toward needle-free drug delivery technologies. Innovations such as jet injectors, microneedle patches, and nasal sprays are reducing patient discomfort while improving compliance. Additionally, 3D printing technology is revolutionizing personalized medicine by allowing the fabrication of patient-specific drug formulations with controlled release profiles. The demand for sustainable and biodegradable drug delivery materials is also gaining momentum, driven by environmental concerns and regulatory pressures. Pharmaceutical companies are increasingly investing in eco-friendly formulations, ensuring that drug delivery methods align with global sustainability initiatives. The convergence of these trends is not only enhancing therapeutic outcomes but also creating new market opportunities for industry stakeholders.

How Are End-Use Applications Shaping the Future of Drug Delivery?

The evolution of drug delivery technologies is closely linked to their application across various medical fields, with different end-use segments driving the market’s growth. Oncology remains one of the most significant areas for innovation, given the complexity of cancer treatment and the need for targeted therapeutics. Advanced drug delivery systems such as antibody-drug conjugates (ADCs), nanocarriers, and polymer-drug conjugates are transforming cancer therapy by improving drug selectivity and reducing systemic toxicity. Similarly, the treatment of central nervous system (CNS) disorders is benefiting from breakthroughs in blood-brain barrier (BBB) penetration technologies, allowing for more effective delivery of neurotherapeutic agents.

Infectious diseases and vaccine development have also become pivotal areas of focus, particularly in light of the COVID-19 pandemic. Lipid nanoparticles (LNPs) have emerged as a breakthrough technology, playing a crucial role in mRNA vaccine delivery. Transdermal and pulmonary drug delivery systems are also gaining traction for their ability to bypass first-pass metabolism, ensuring higher bioavailability of therapeutics. The growing preference for home healthcare and self-administration is further bolstering demand for auto-injectors, wearable infusion pumps, and pre-filled syringes, catering to the needs of an aging population and individuals with chronic conditions. As end-use applications continue to diversify, pharmaceutical companies are investing in research and development to tailor drug delivery mechanisms to specific therapeutic areas, ensuring optimal treatment efficacy across a wide spectrum of diseases.

What Factors Are Fueling the Expansion of the Drug Delivery Market?

The growth in the pharmaceutical drug delivery market is driven by several factors, primarily centered around technological innovations, increasing chronic disease prevalence, and the rising demand for personalized medicine. The surge in biologics and biosimilars is a major driver, necessitating advanced drug delivery solutions that ensure stability and efficacy of large-molecule therapeutics. The proliferation of smart drug delivery devices, including connected inhalers and wearable injectors, is further accelerating market expansion by enhancing treatment adherence and offering real-time health monitoring capabilities. Additionally, the rise of nanotechnology in drug formulations is enabling precision medicine approaches, allowing for targeted drug delivery and reduced systemic exposure.

Regulatory support for patient-centric drug delivery solutions is also playing a crucial role in market growth. The shift toward self-administrative devices, such as auto-injectors and pre-filled syringes, is being driven by the need to reduce hospital dependency and streamline treatment regimens for patients with chronic illnesses. The integration of AI and machine learning in drug delivery systems is enhancing predictive analytics, enabling healthcare providers to optimize dosing schedules and minimize adverse effects. Furthermore, advancements in 3D printing technology are facilitating the development of customized drug formulations, improving therapeutic outcomes for diverse patient populations. As pharmaceutical companies continue to invest in research and development, the convergence of these factors is expected to propel the pharmaceutical drug delivery market into a new era of innovation and accessibility.

SCOPE OF STUDY:

The report analyzes the Pharmaceutical Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Administration, Injectable Administration, Topical Administration, Ocular Administration, Pulmonary Administration, Other Administration Routes); Application (Cancer Application, CVD Application, Diabetes Application, Respiratory Diseases Application, CNS Disorders Application, Autoimmune Diseases Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â